The company is expected to release the results from the Phase I/II clinical trials this month.

It is also developing a vaccine with U.S. biotech firm Translate Bio, with clinical human trials expected to start this month.

(Reporting by Matthias Blamont in Paris; Writing by Josephine Mason in London; Editing by Jon Boyle)